33 results
8-K
EX-99.1
VSTM
Verastem Inc
24 May 24
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024
7:01am
. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease. LGSOC affects younger women with bimodal peaks of diagnosis
8-K
EX-99.1
VSTM
Verastem Inc
9 Apr 24
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
5:10pm
Ovarian Cancer
15 LGSOC Unmet Need & Opportunity LGSOC is a less common type of ovarian cancer that is often diagnosed in younger women o LGSOC … is a type of ovarian cancer that disproportionately affects younger women Patients often experience significant pain and suffering from their disease
8-K
EX-99.1
VSTM
Verastem Inc
12 Sep 23
Corporate Presentation September 2023
4:08pm
, unpublished
7 LGSOC Unmet Need & Opportunity LGSOC is a less common type of ovarian cancer that is often diagnosed in younger women o LGSOC is a unique … for patients with recurrent LGSOC with a promising safety profile to date. It is particularly encouraging to see extensive tumor shrinkage in women who have
8-K
EX-99.1
VSTM
Verastem Inc
8 Jun 23
Corporate Presentation June 2023
5:24pm
cancer that is often diagnosed in younger women o LGSOC is a unique disease that is distinct from high - grade serous ovarian cancer (HGSOC) in its … tumor shrinkage in women who have had sever al treatment lines, including prior MEK inhibitors. These latest findings suggest the combination may offer
8-K
EX-99.1
fy5mcwemr833yis hht6
25 May 23
Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer
5:18pm
8-K
EX-99.1
spep thjce6
4 Oct 22
Corporate Presentation October 2022
4:20pm
8-K
EX-99.2
feihpca 85
6 Jun 22
Corporate Presentation June 2022
7:58am
8-K
EX-99.1
7fwii3 27py0
6 Jun 22
Corporate Presentation June 2022
7:58am
8-K
EX-99.1
rwleiro2f ke
11 Jan 22
Corporate Presentation January 2022
4:15pm
8-K
EX-99.1
c203 5f6nbq9
26 May 21
Regulation FD Disclosure
8:34am
8-K
EX-99.1
l19 7kfscsg4hbjt
25 Feb 21
Regulation FD Disclosure
12:00am
8-K
EX-99.1
flxd6 b60lry3zm
17 Dec 20
Regulation FD Disclosure
9:31am
8-K
EX-99.3
e8e78kxe
16 Sep 20
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit
8:47am
8-K
EX-99.1
40xcdu
29 Oct 19
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
9:28pm